Compass Lexecon Client the City of Baltimore Awarded Over $260 Million after Jury Determines that Opioid Distributors’ Conduct Contributed to a Public Nuisance
Latest cases
Green light for JD Sports to acquire French sportswear retailer Courir
Latest cases
Compass Lexecon Client, The Federal Trade Commission, Granted Preliminary Injunction Pausing the Proposed Merger of Tapestry and Capri
Court Relies Heavily on Testimony of Compass Lexecon Executive Vice President Dr. Loren K. Smith
Latest cases
Prysmian Group Obtains Approval to Acquire Encore Wire Corporation
Latest cases
Unconditional approval for $3 billion merger between Chilean financial institutions Bicecorp and Grupo Security
Latest cases
Energy and climate transition: How to strengthen the EU’s competitiveness
Latest cases
Haier Smart Home secures unconditional clearance for Carrier Commercial Refrigeration acquisition under the new FSR regime
Latest cases
PBMs and Prescription Drug Distribution: An Economic Consideration of Criticisms Levied Against Pharmacy Benefit Managers
Compass Lexecon worked closely with the merging parties on this matter, starting with a team advising Horizon on the merger (led by Compass Lexecon expert Mark Israel) and proceeding to the…
On December 17, 2020, the U.S. District Court for the District of Kansas granted summary judgment in favor of Compass Lexecon’s client Mylan Inc. on antitrust claims brought by Sanofi-Aventis…
On August 28, 2017, the District Court in this case denied Plaintiffs’ motion to certify a class of direct purchasers of Cephalon’s branded drug Provigil.
Compass Lexecon supported Schering-Plough in a case involving K-Dur, demonstrating economic insights that led to denial of class certification for plaintiffs.
Our professionals
Compass Lexecon’s staff includes more than 850 employees, including professional consultants, analysts, and practice support personnel that span 23 offices across the globe.
